How calcium signaling helps the immune system detect tuberculosis
MR1-dependent presentation of Mycobacterium tuberculosis: a unique role for calcium signaling
This study is looking at how our immune system spots and fights tuberculosis by focusing on a special molecule called MR1, and it aims to find new ways to boost our immune response against the infection.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10837043 on NIH RePORTER |
What this research studies
This research investigates how the immune system identifies and responds to tuberculosis infections, focusing on a specific molecule called MR1 that presents antigens to T cells. The study explores the role of calcium signaling in the process of MR1 sampling intracellular environments to detect the presence of the bacteria. By understanding these mechanisms, researchers aim to uncover new ways to enhance immune responses against tuberculosis. The approach involves examining the trafficking of proteins and calcium channels that are sensitive to changes in calcium levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of or currently infected with tuberculosis.
Not a fit: Patients with non-infectious diseases or those not affected by tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for detecting and treating tuberculosis infections.
How similar studies have performed: Other research has shown promise in understanding immune responses to intracellular infections, but the specific role of MR1 and calcium signaling in tuberculosis is a novel area of investigation.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Karamooz, Elham — Oregon Health & Science University
- Study coordinator: Karamooz, Elham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.